Brief: Kashiv Biosciences submits Biologics License Application to the U.S. FDA and receives European Medicines Agency acceptance for ADL-018
06/10/2025 13:09
Oct 6 (Reuters) - Alvotech SA ALVO.O: KASHIV BIOSCIENCES ANNOUNCES SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO U.S. FDA AND ACCEPTANCE OF MARKET AUTHORIZATION APPLICATION BY EUROPEAN MEDICINES AGENCY FOR ADL-018, A PROPOSED BIOSIMILAR TO XOLAIR® (OMALIZUMAB) Source text: ID:nBwblfJYra Further company coverage: ALVO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amneal Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-3M Company, Constellation Energy, Metropolitan Bank Holding
US FDA is working with manufacturers to boost estrogen patch supply amid access concerns (updated)
U.S. RESEARCH ROUNDUP- Intuit, MongoDB, Zscaler
U.S. STOCKS ON THE MOVE-Mastercard, Yum, Equinix
Amneal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary